United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop.

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

Envestnet Portfolio Solutions Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 8.1% during the fourth quarter, according to its most recent Form 13F filing with the ...

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

Leerink analyst Roanna Ruiz lowered the firm’s price target on United Therapeutics (UTHR) to $420 from $430 and keeps an Outperform rating on the shares. United Therapeutics’ Q4 earnings ...

Shares of United Therapeutics fell on pace for the largest percent decrease in three years after the company's fourth-quarter earnings fell short of expectations. The stock was down 10% ...

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported fourth-quarter net income of $301.3 million. The Silver Spring, Maryland-based ...